Clinical trials: Nebulization
Pulmonary Arterial Hypertension
Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution
This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult…
- Trial name
- NCT04903730
- Testing
- AER-901 Solution for Nebulization
- Where
- Australia
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Aerami Therapeutics
Asthma
Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01577953
- Testing
- SB010
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Asthma
Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children
To determine whether addition of ipratropium bromide to salbutamol nebulisations produces significantly greater bronchodilation in young children presenting to an emergency department with an acute attack of asthma
- Trial name
- NCT02235428
- Testing
- Ipratropium bromide, Salbutamol
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease (COPD), Lung Disease Chronic, Lung Diseases, Obstructive
- Trial name
- AERODUO-2 (NCT07896252)
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- AeroRx Therapeutics Inc.
Upper Resp Tract Infection, Rhinitis Acute
Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children
The purpose of this study is to evaluate the tolerance, the performance and safety of this device, 22‰ Hypertonic seawater aerosol therapy solution in unidose container, to treat adult and peadiatric patients with of upper…
- Conditions
- Upper Resp Tract Infection, Rhinitis Acute, Rhinopharyngitis, Cold Symptom
- Trial name
- AIR (NCT07267689)
- Testing
- Treatment (22‰ Hypertonic seawater aerosol therapy solution)
- Where
- 4 sites in Poland
- Volunteers
- 110 people
- Sponsor
- Laboratoires Gilbert
Cystic Fibrosis
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare…
- Trial name
- CT03 Core (NCT00885365)
- Testing
- tobramycin / Bramitob, tobramycin / TOBI
- Where
- 44 sites in Czechia, France and 6 more
- Volunteers
- 324 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01554319
- Testing
- SB010
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Asthma
Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.
To evaluate the safety and tolerability of S-1226 composed of perflubron with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered over 2 minute nebulisation to healthy subjects.
- Trial name
- NCT02616770
- Testing
- S1226 (4%), Saline (for 4%), S1226(8%)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SolAeroMed Inc.
Asthma
Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma
What is the goal of this study? The goal of this clinical trial is to find out whether the study drug LQ036 (a nebulized solution taken by inhaling through a nebulizer) works to improve lung function and asthma control in people…
- Trial name
- NCT07589439
- Testing
- LQ036
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Shanghai Novamab Biopharmaceuticals Co., Ltd.
Asthma
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma
The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.
- Trial name
- NCT01584726
- Testing
- Magnesium Sulfate
- Where
- 2 sites in Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
Bronchial Asthma
Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms
To demonstrate a superior efficacy of BDP plus rescue salbutamol suspension for nebulisation, compared to placebo plus rescue salbutamol, in the relief of symptoms of asthma in young children with persistent symptoms of asthma.
- Trial name
- NCT00497523
- Testing
- Beclomethasone dipropionate, Beclomethasone dipropionate/Salbutamol combination, Salbutamol
- Where
- 19 sites in Poland, Ukraine
- Volunteers
- 283 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.
- Trial name
- S-1226(8%) (NCT02334553)
- Testing
- S1226(8%)
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- SolAeroMed Inc.
Cystic Fibrosis
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
This Phase 1/2, first-in-human study evaluated the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with cystic fibrosis (CF).
- Trial name
- RESTORE-CF (NCT03375047)
- Testing
- MRT5005, Normal saline
- Where
- 16 sites in United States
- Volunteers
- 42 people
- Sponsor
- Sanofi
Croup
Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup
Acute laryngotracheobronchitis, better known as croup, is one of the common respiratory complaints among children and the most common cause of airway obstruction in children aged six months to six years.
- Trial name
- NCT00938353
- Testing
- beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cystic Fibrosis
A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
This is a 48-week extension study to CMA-0631-PR-0010 Core Study. Patients who have a positive culture for P. aeruginosa at visit 4 of the first 8-week core study period and/or if deemed appropriate by the Investigators will be…
- Trial name
- CT03Ext (NCT01111383)
- Testing
- tobramycin
- Where
- 20 sites in France, Poland and 1 more
- Volunteers
- 209 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD (Chronic Obstructive Pulmonary Disease)
Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 1, single-dose, 2-period crossover study in healthy volunteers to compare the systemic pharmacokinetic (PK) profile of inhaled AERO-002 versus inhaled active comparator product.
- Trial name
- NCT07802730
- Testing
- AERO-002 (60 mcg), Glycopyrrolate (18 mcg)
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.
Cystic Fibrosis
Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study
This study assesses the aerosol delivery characteristics (measured by in vivo lung deposition, nebulization time, serum tobramycin concentrations, and pharmacokinetic parameters) and safety of tobramycin inhalation solution…
- Trial name
- NCT00399945
- Testing
- Tobramycin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis
COPD
Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD
This is a phase 1/phase 2a, single dose, crossover study conducted in two parts. Part 1: Phase 1, open-label, 4-period crossover study in 8 healthy subjects to determine the optimal dose of AERO-001 and AERO-002, the active…
- Trial name
- NCT06841640
- Testing
- AERO-001, AERO-002, AERO-007
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.
Allergic Asthma
Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics
This is a single centre, double-blind, randomised, parallel group, repeated dose asthmatic subjects. Subjects will receive AER 001 (60 mgs) or placebo twice daily for 28 days.
- Trial name
- NCT00535431
- Testing
- AER 001
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Aerovance, Inc.
COVID-19 Acute Respiratory Distress Syndrome
Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog)…
- Trial name
- NCT05083117
- Testing
- XW001
- Where
- 2 sites in Argentina, Peru
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.